Comparative Pharmacokinetic Trial of RGB-03 and MabThera
Launched by GEDEON RICHTER PLC. · Feb 19, 2015
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Active Rheumatoid Arthritis
- • Inadequate response or intolerance to other DMARDs and anti-TNFs
- • Treatment with Methotrexate
- Exclusion Criteria:
- • Previous treatment with rituximab
- • Patients with systemic manifestations of rheumatoid arthritis
- • Patients seropositive for HIV, HCV, HBV
- • Female patients nursing
- • Other protocol-defined inclusion/exclusion criteria may apply.
About Gedeon Richter Plc.
Gedeon Richter Plc is a leading global pharmaceutical company headquartered in Hungary, renowned for its commitment to innovation and excellence in healthcare. With a strong focus on women's health, central nervous system disorders, and biosimilars, Gedeon Richter specializes in the research, development, manufacturing, and marketing of a diverse portfolio of pharmaceutical products. The company is dedicated to advancing medical science through rigorous clinical trials and collaborations, aiming to deliver high-quality therapeutic solutions that address unmet medical needs worldwide. Its robust pipeline and strategic partnerships underscore its mission to enhance patient outcomes and contribute to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
